Research · Sep 3, 2026
[CORT] Corcept Therapeutics Thesis 2026: Korlym Funds a Next-Generation Cortisol Modulator Across Cushing's and Cancer
Corcept Therapeutics Incorporated (NASDAQ: CORT) is a Menlo Park, California-headquartered specialty biopharmaceutical company focused on discovery and development of drugs that modulate cortisol activity — a single-mechanism focus that has driven a two-decade build into a profitable mid-cap biopharma. The company was co-founded in 1998 by Joseph Belanoff (a Stanford-trained psychiatrist) and Alan Schatzberg (a renowned psychiatry researcher) with the hypothesis that excess cortisol signaling drives a range of serious diseases (Cushing syndrome — the obvious one — but also psychiatric depression, oncology adjuncts, metabolic disease, others), and that selectively modulating the glucocorticoid receptor (GR) could provide therapeutic benefit. Belanoff has been CEO since founding — an unusually long-tenured biotech leader. Corcept's only marketed product is Korlym (mifepristone) — a non-selective cortisol-receptor antagonist (also a progesterone antagonist — the abortifacient label restriction is a meaningful commercial constraint) — FDA-approved February 2012 for hyperglycemia secondary to endogenous Cushing syndrome in adults with T2DM or glucose intolerance who have failed surgery or are not candidates for surgery. Korlym has scaled into a ~$700M+ annual franchise growing ~10-15% annually for a decade through patient-finder initiatives Corcept funds at endocrinologist offices, prescriber education, and disciplined pricing. The company has invested heavily in the relacorilant pipeline — a next-generation selective glucocorticoid antagonist designed to avoid mifepristone's progesterone-receptor effects — with two Phase 3 programs: GRACE Cushing trial (NDA filed/under FDA review, potential approval that would replace Korlym) and ROSELLA platinum-resistant ovarian-cancer trial (the headline pipeline binary). Capital structure net-cash with no debt and aggressive shareholder-return allocation. CORT enters FY2026 with FY2025 revenue selected various aggregate ~$740-820M (~12-15% growth), aggregate adjusted EPS ~$1.30-1.65, adjusted EBITDA ~$160-220M, under co-founder/CEO Joseph Belanoff. The first thesis pillar is the Korlym franchise — entirety of commercial revenue (~$700M+ annually) and the funding engine for relacorilant: Korlym (mifepristone) is a small-molecule oral antagonist of the glucocorticoid receptor blocking cortisol's effects at receptor level; FDA-approved 2012 for hyperglycemia secondary to endogenous Cushing syndrome in adults with T2DM/glucose intolerance failed/non-candidates for surgery; mifepristone also a progesterone-receptor antagonist (hence its better-known use as abortifacient Mifeprex at higher doses) — progesterone activity creates label restriction (black-box on termination of pregnancy, not used in fertile women without contraception) limiting commercial breadth; endogenous Cushing syndrome is rare — ~20-30K+ US patients diagnosed (likely many more undiagnosed) — chronic excess cortisol driving weight gain, hyperglycemia, hypertension, mood changes, osteoporosis — diagnosis challenging, patients presenting to endocrinologists/psychiatrists/PCPs with non-specific symptoms (depression, T2DM, hypertension) and cortisol dysregulation missed for years; patient-finder initiative funds endocrinologist screening programs (genetic testing, cortisol protocols, clinical screening) identifying previously-undiagnosed patients — multi-year growth driver; commercial model — high-priced specialty drug (~$120-180K+ patient-year), ~95%+ gross margins, dedicated rare-disease salesforce, payer management; FY2025 dynamics are Korlym revenue ~12-15% growth (patient adds + pricing), prescriber base expanding, gross margin very high, operating leverage (R&D growing on relacorilant but ahead of commercial costs); FY2026 catalyst is continued patient adds (~10-15% pattern), relacorilant Cushing NDA decision (if approved, transition Cushing patients to relacorilant — major franchise upgrade with cleaner safety, no abortifacient restriction, expanded breadth, extended IP), generic-mifepristone dynamics (Teva and others launched generics — though rare-disease specialty channel mitigates), pipeline progression; risks/competitors are generic mifepristone overhang, relacorilant transition risk (transition discount could compress revenue temporarily), broader Cushing landscape — Recordati's Isturisa (osilodrostat) for Cushing-disease pituitary form, older generics (ketoconazole, etomidate, metyrapone), Crinetics (CRNX, Cushing pipeline), Xeris Biopharma (XERS); comp set Recordati (REC.MI), Crinetics (CRNX), Strongbridge/Xeris (XERS), Sparrow Pharmaceuticals (private), and specialty Insmed (INSM), Vanda (VNDA), Argenx (ARGX), Ultragenyx (RARE). The second pillar is the relacorilant pipeline — next-generation cortisol modulator: relacorilant is oral once-daily selective glucocorticoid antagonist blocking GR without antagonizing PR (eliminating progesterone-related effects constraining mifepristone); GRACE Phase 3 trial — randomized placebo-controlled in adults with endogenous Cushing syndrome with hyperglycemia and/or hypertension — positive top-line (statistically significant on glucose, BP, weight + clean safety), NDA filed, FDA review with potential 2026 PDUFA decision — if approved relacorilant becomes franchise-defining (replacing Korlym, IP protection extending well into 2030s+); ROSELLA Phase 3 trial — relacorilant + nab-paclitaxel vs nab-paclitaxel monotherapy in platinum-resistant ovarian cancer — tough setting where new active agents scarce, mechanism rationale that glucocorticoid signaling promotes taxane resistance and relacorilant GR antagonism re-sensitizes — Phase 2 showed encouraging PFS — registrational with data readout expected 2026 (transformatively expands TAM if positive); other pipeline — relacorilant in other oncology, dazucorilant (ALS), additional cortisol-modulator molecules in earlier-stage metabolic/neurology/oncology; FY2025 dynamics are GRACE NDA under review, ROSELLA completing/maturing, earlier-stage progressing, R&D intense; FY2026 catalyst is GRACE NDA decision (likely first H1 2026 PDUFA — major near-term commercial), ROSELLA readout (major asymmetric pipeline-value event), pipeline progression, possible BD activity; risks are ROSELLA failure (mixed Phase 2 + tough setting — meaningful risk), GRACE setback (FDA additional info), relacorilant-transition execution from Korlym, pipeline risk, capital-allocation discipline; comp set: relacorilant has no late-stage selective GR antagonist competitor, Cushing comps Recordati (REC.MI), Crinetics (CRNX), PROC oncology GSK (GSK Zejula), AstraZeneca (AZN Lynparza), Genentech (Tecentriq), AbbVie (ABBV — ImmunoGen Elahere); broader specialty Insmed (INSM), Krystal (KRYS), Argenx (ARGX), Ultragenyx (RARE). The capital story: net-cash shareholder-return-rich (unusual for specialty biopharma) — no dividend (cash to R&D + pipeline + buybacks), aggressive opportunistic buybacks (share count down from ~120M+ to ~100-105M, multi-year programs consistently executed), substantial net cash ~$450-600M+ (no meaningful debt — historically debt-free), excellent FCF conversion (Korlym high-margin specialty + low SG&A), capital priorities fund R&D (relacorilant Phase 3 + pipeline) → aggressive buybacks → maintain net cash → possible bolt-on M&A or BD, with relacorilant-driven R&D pace, cash deployment, and eventual Korlym-to-relacorilant transition as principal considerations. At ~$50-100 per share on ~100-105M shares (~$5-10B equity, ~$4.5-9.5B EV given net-cash) CORT trades at roughly ~30-65x P/E (broad range — non-GAAP vs GAAP + binary pipeline), ~25-50x EV/EBITDA — premium specialty-pharma multiple reflecting relacorilant pipeline optionality (esp. ROSELLA) + Korlym franchise persistence + IP-extension via relacorilant + strong balance sheet — versus Recordati (REC.MI), Crinetics (CRNX), Xeris (XERS) in Cushing; Insmed (INSM), Vanda (VNDA), Argenx (ARGX), Ultragenyx (RARE), Krystal (KRYS), BridgeBio (BBIO), Apellis (APLS) in specialty; GSK (GSK), AstraZeneca (AZN), AbbVie (ABBV) in PROC oncology. FY2026 base case: ~$840-940M+ revenue + ~$1.50-1.95 adj. EPS + Korlym continued growth + relacorilant Cushing NDA decision pending + ROSELLA readout binary + continued buybacks + cash building; bull case: ~$900-1.05B+ revenue + ~$1.75-2.40+ adj. EPS on relacorilant Cushing approved + ROSELLA positive (transformative oncology) + Korlym continued growth + modest generic impact + aggressive buybacks + possible accretive M&A + substantial re-rating; bear case: ~$650-760M revenue + ~$0.85-1.25 adj. EPS on ROSELLA failure (major asymmetric downside — eliminates oncology optionality) + GRACE setback (delaying transition) + accelerated generic-mifepristone share losses + pipeline setbacks + compression. The thesis depends on the Korlym commercial pipeline (Cushing patient identification + prescription growth + generic defense + relacorilant transition prep) plus the relacorilant pipeline (GRACE approval + ROSELLA readout + IP extension + indication exploration) plus net-cash balance sheet plus aggressive buybacks plus Joseph Belanoff's multi-decade co-founder stewardship of the cortisol-modulator platform.